Connect with us


Europe’s cannabis market to hit €3.2 billion by 2025



Prohibition Partners expect greater patient access to fuel a 64% growth rate over the next four years.

The European cannabis market is projected to hit a staggering €3.2 billion by 2025 in a new report.

Industry consultants Prohibition Partners expect greater patient access across the continent to fuel a 64% growth rate over the next four years.

Germany will continue to dominate the European market until 2024 but the UK and France are predicted to make up a bigger share towards the end of the period.

UK medical cannabis market could show the most significant growth of any country in Europe by 2025 if regulations continue to open up, the analysis finds.

The sixth edition of the European Cannabis Report looks at patient numbers, legislative changes and industry patterns to provide a medium-term outlook.

Around 60,000 European patients accessed medicinal cannabis products for the first time in 2020, bringing the total number of patients to 185,000.

Stephen Murphy, co-founder and CEO of Prohibition Partners, said: “Europe is beginning to realise its potential as the world’s leading cannabis market. 

“Since the first edition of The European Cannabis Report published four years ago, enormous progress has been made for patient access and cannabis education. 

“We are only at the very start of our journey of cannabis in Europe but there is irrefutable momentum towards becoming the world’s largest cannabis market, it is only a matter of time. 

“The European Cannabis Report sixth Edition does a fantastic job informing the reader on the status of the industry in Europe, providing the context for growth and mapping out the roadmap for all stakeholders.”

The report also identifies several European nations that could introduce legal access to recreational cannabis by 2025, including Netherlands, Switzerland and Germany. Sales of adult-use cannabis could be worth over €500 million by 2025.


Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.